For how we live.
A surveillance analysis of WHO data from January 2024 to February 2026 tracks the clade Ib emergency from declaration to its end, and finds reported spread continued after the emergency was formally lifted.
A modelling study of Koungou village, calibrated to daily cases by vaccination status, estimates CVD 103-HgR prevented 87% of cholera and averted hundreds of cases — a first real-world test of a challenge-trial vaccine.
A Global Burden of Disease analysis of Kenya's 47 counties found ischaemic stroke killed 11,328 people in 2023 — death rates are falling even as new cases rise, with raised blood pressure behind 35% of the burden.
Surveillance across seven countries detected Shigella by PCR in 20.0% of diarrhoea episodes in toddlers, and found ciprofloxacin resistance reaching 37.2% — a warning for a disease with no licensed vaccine.
A phase 2b trial in 4936 Gambian children missed its primary endpoint, but ETVAX cut moderate-to-severe ETEC diarrhoea by 80.6% once parasite co-infections were excluded.
In the pragmatic BEAT Tuberculosis trial, an all-oral six-month regimen cured 86.1% of patients with rifampicin-resistant TB — statistically non-inferior to the nine-month standard, with similar safety.
A national cohort of 3,584,203 people found that 96.4% of those re-tested still had a viral load below 1000 copies per mL a year later — the threshold at which HIV is not transmitted sexually.
A national survey of more than 120,000 children put combined prevalence at 5.4% and heavy-intensity infection below WHO's 1% elimination threshold, after ten years of preventive chemotherapy.
A review of the Africa CDC and WHO response reports 49,803 confirmed cases and 240 deaths across 28 countries, US$977 million mobilised, and just 32% of 3.1 million delivered vaccine doses administered.
Two WHO-endorsed shots are now available, but a new analysis argues the harder problem is financing them in the lowest-income, highest-burden countries. Nigerian rollout data shows demand outpacing readiness.
The Global Burden of Disease 2023 study estimates 2.33 billion NCD incident cases and 263 million DALYs across Africa, with high blood pressure the single largest driver of the continent's NCD deaths.
In the LATA trial across four countries, 0.9% of teens on long-acting cabotegravir–rilpivirine lost viral suppression by 96 weeks, versus 6.4% on daily tablets — a superiority result.
By 2023, 22% of children in Mali and 16% in Chad had received no routine vaccine at all, an analysis of WHO figures found, with measles coverage stuck below 90% across most of the belt.
External validation of the PAANTHER decision algorithm in 277 children across four African countries recorded 93.3% negative predictive value and 97.4% sensitivity against a composite reference standard.
A meta-analysis of 56 trials and 134,424 children finds RTS,S and R21 cut clinical malaria by about a third overall, with efficacy strongest alongside seasonal chemoprevention and waning after 36 months.
A descriptive study using WHO modelled estimates for 2022 put current cigarette use between 1.7% in Ghana and 18.2% in Seychelles, with the male-female gap reaching 36.4 points in Lesotho.
Tungiasis, on WHO's neglected-disease list since 2021 but never quantified, costs up to 379,645 healthy life-years a year — rising to 575,298 once its complications are counted.
THESUS-HF II enrolled 1,578 patients across 50 hospitals in 17 countries. Guideline drugs were prescribed at discharge in most patients, and target doses were reached in fewer than half.
National surveillance shows no decline from 2020 to 2024, with one in five patients already disabled at diagnosis — a marker of late detection even as the global burden falls.
A frontier analysis of two decades attributes 97.6% of nutritional disparities between countries to inefficiency rather than to resources. The policy reading is contestable; the decoupling is not.
A case-control study by MSF's Epicentre and WHO put NmCV-5's adjusted effectiveness at 92% against meningococcal meningitis after 2024 campaigns in Niger — on a small sample of 17 confirmed cases.
A cluster-randomised trial in Saponé found seasonal chemoprevention given to children up to age 10 nearly halved parasite carriage in 5-to-9-year-olds, though supervised delivery brought no clear gain under age five.
A peer-reviewed account traces the mass screening and tsetse-fly control that cut gambiense sleeping sickness below one case per 10,000 in endemic areas — the threshold WHO validated in January 2025.
A WHO global update logged 79 human infections in the Americas and 16 confirmed cases in Africa by late May, with the virus surfacing in areas long considered free of it.
WHO's latest tally puts the 2026 year-to-date count at 58,740 cases and 732 deaths across 22 countries, down sharply from last year except in conflict-affected states.
Two doses of the long-acting antibody L9LS protected under-fives in a high-transmission area, but researchers say a higher dose is likely needed for stronger cover.
The AVENIR trial met its resistance endpoint in the gut but not the nose: giving the antibiotic to under-fives lifted macrolide resistance 16% above placebo communities.
The surveillance behind the WHO-verified milestone is now published: no infective blackflies at any monitored site, and no infection among 16,406 children tested.
WHO's World malaria report counts 282 million cases and 610,000 deaths for 2024. The US$3.9 billion spent was under half the US$9.3 billion the global strategy called for.
WHO has graded the regional resurgence a level 2 emergency. Only 5.7% of the 20,412 suspected cases were laboratory-confirmed, and the antitoxin that prevents most deaths is in global short supply.
A high-resolution model of East Africa's most densely settled basin finds that two-thirds of the projected rise in exposure comes from temperature and population growth acting together.
Across 165 clinics in four African countries, HIV testing fell by up to 35% and treatment starts by up to 32%. Most services had not returned to baseline two months after the orders were lifted.